Seamus Fernandez
Stock Analyst at Guggenheim
(4.71)
# 152
Out of 5,134 analysts
119
Total ratings
61.63%
Success rate
34.12%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $72 | $60.35 | +19.30% | 14 | Feb 6, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $5.15 | +424.27% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $53.33 | +117.51% | 5 | Feb 2, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,161 | $1,036.05 | +12.06% | 23 | Jan 20, 2026 | |
| GPCR Structure Therapeutics | Maintains: Buy | $90 → $140 | $71.41 | +96.05% | 3 | Jan 20, 2026 | |
| MBX MBX Biosciences | Maintains: Buy | $77 → $88 | $39.38 | +123.46% | 5 | Jan 16, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $14 → $25 | $12.48 | +100.32% | 3 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $120 → $140 | $102.53 | +36.55% | 3 | Dec 17, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $46.43 | - | 1 | Dec 9, 2025 | |
| IVA Inventiva | Maintains: Buy | $13 → $11 | $6.08 | +80.92% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.40 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $25 | $14.13 | +76.93% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $69.64 | +66.57% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $26.61 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $27.94 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $121.57 | +0.35% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $60.87 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.50 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $49.37 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $166.17 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.10 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $3.26 | +1,556.44% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $22.94 | +96.16% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $209.48 | -81.86% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $27.37 | +38.84% | 3 | Jan 31, 2018 |
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $72
Current: $60.35
Upside: +19.30%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $5.15
Upside: +424.27%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $53.33
Upside: +117.51%
Eli Lilly and Company
Jan 20, 2026
Maintains: Buy
Price Target: $1,163 → $1,161
Current: $1,036.05
Upside: +12.06%
Structure Therapeutics
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $71.41
Upside: +96.05%
MBX Biosciences
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $39.38
Upside: +123.46%
Tenax Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $14 → $25
Current: $12.48
Upside: +100.32%
Rhythm Pharmaceuticals
Dec 17, 2025
Maintains: Buy
Price Target: $120 → $140
Current: $102.53
Upside: +36.55%
Sanofi
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $46.43
Upside: -
Inventiva
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $6.08
Upside: +80.92%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $7.40
Upside: -
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $14.13
Upside: +76.93%
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $69.64
Upside: +66.57%
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $26.61
Upside: -
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $27.94
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $121.57
Upside: +0.35%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $60.87
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.50
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $49.37
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $166.17
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.10
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $3.26
Upside: +1,556.44%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $22.94
Upside: +96.16%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $209.48
Upside: -81.86%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $27.37
Upside: +38.84%